A Phase II Study to Evaluate the Use of the MEK Inhibitor Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07891286

Title field or adapter rule

{'original_value': 'A Phase II Study to Evaluate the Use of the MEK Inhibitor Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:29.639172+00:00

Published At

2026-10-29T00:00:00+00:00

Record Updated At

2026-10-29

Source Retrieved At

2026-10-31T22:18:13.198083+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["LGCMN", "Large and Giant Congenital Melanocytic Nevi", "NF1", "Solid Tumor", "Pediatric Tumors", "Neurocutaneous Melanocytosis", "Congenital Melanocytic Nevus", "Arachnoid Cysts", "Astrocytoma", "Ependymoma", "Melanoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-29", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07891286"

protocolSection.identificationModule.officialTitle

"A Phase II Study to Evaluate the Use of the MEK Inhibitor Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults"

protocolSection.statusModule.overallStatus

"NOT_YET_RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• LGCMN (protocolSection.conditionsModule.conditions)
• Large and Giant Congenital Melanocytic Nevi (protocolSection.conditionsModule.conditions)
• NF1 (protocolSection.conditionsModule.conditions)
• Solid Tumor (protocolSection.conditionsModule.conditions)
• Pediatric Tumors (protocolSection.conditionsModule.conditions)
• Neurocutaneous Melanocytosis (protocolSection.conditionsModule.conditions)
• Congenital Melanocytic Nevus (protocolSection.conditionsModule.conditions)
• Arachnoid Cysts (protocolSection.conditionsModule.conditions)
• Astrocytoma (protocolSection.conditionsModule.conditions)
• Ependymoma (protocolSection.conditionsModule.conditions)
• Melanoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Arm 1'], 'description': 'Mirdametinib dosage will be 2-4 mg/m2/dose orally twice daily.', 'name': 'Mirdametinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Mirdametinib (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.